Production (Stage)
Anika Therapeutics, Inc.
ANIK
$11.24
-$0.53-4.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -33,897.73% | 98.05% | 92.83% |
| Total Depreciation and Amortization | -- | -- | 6.32% | -0.24% | -42.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | 524.71% | -23.08% | -90.10% |
| Change in Net Operating Assets | -- | -- | 118.55% | -92.44% | -60.05% |
| Cash from Operations | -- | -- | 569.22% | -748.41% | -103.46% |
| Capital Expenditure | -- | -- | 64.27% | -88.22% | 1.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 46.64% | -88.22% | 1.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | 1,917.39% | -93.13% |
| Repurchase of Common Stock | -- | -- | -153.40% | 31.40% | -32,900.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -259.23% | 51.12% | -764.62% |
| Foreign Exchange rate Adjustments | -- | -- | 250.45% | -622.58% | -140.79% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | 92.18% | -37.02% | -291.25% |